Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Research on elamipretide (SS-31) has expanded across multiple therapeutic areas, with studies examining its effects on mitochondrial dysfunction in various disease models.
Neurological Applications
Several preclinical studies have investigated elamipretide's neuroprotective properties. A mouse study examined combination therapy with elamipretide and nicotinamide mononucleotide for post-ischemic brain injury, targeting TREM2 pathways. Another study evaluated elamipretide's effects on spinal cord injury recovery, focusing on mitochondrial bioenergetics preservation and neural remodeling. Research has also explored elamipretide's potential in neurodegenerative disease, with one study examining its ability to modulate α-synuclein membrane binding and aggregation while restoring mitochondrial function.
In aged rats, researchers investigated elamipretide's protective role against endothelial glycocalyx degradation, neuroinflammation, and cognitive impairment.
Cardiovascular Research
A rat model study examined elamipretide's effects on skeletal muscle performance in heart failure with preserved ejection fraction (HFpEF), targeting mitochondrial dysfunction as a therapeutic mechanism.
Other Applications
Research has extended to respiratory conditions, with one study investigating elamipretide's mechanisms alongside N-acetylcysteine for ozone-induced airway hyperresponsiveness and mucus hypersecretion. Additionally, studies have explored mitochondria-targeted approaches for hepatic ischemia-reperfusion injury, though specific sample sizes were not provided in the available evidence.
Clinical Development
One completed Phase 1/2 clinical trial (NCT05168774) investigated elamipretide in Friedreich's ataxia patients, though detailed results and participant numbers are not available in the provided evidence.
Note: Sample sizes and specific study designs were not detailed in the available evidence for most studies. This synthesis reflects research published primarily in 2025-2026, indicating ongoing active investigation of elamipretide across multiple therapeutic areas.